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ABSTRACT  
Dietary yeast supplementation has been reported to influence immune responses in multiples 
species, including horses, with mixed results.  In this study, sixteen Quarter Horse mares (10.6 ± 
5.0 yrs.) were used to evaluate the effect of dietary yeast supplementation on immunoglobulin 
concentrations in response to vaccination.  Mares were blocked by reproductive status and diet 
and randomly assigned to one of two treatment groups: Yeast or Control.  Open mares received 
0.5% BW of a 12% CP pelleted concentrate while pregnant mares received 0.5% BW of a 16% 
CP pelleted concentrate.  All horses also received mixed grass hay and water ad libitum.   Horses 
in the yeast treatment group were fed a target dose of 1 g/45.4 kg of BW per day of a live culture 
of Saccharomyces cerevisiae throughout the study.   After 60d (d 300 of gestation), mares were 
vaccinated with a commercial equine tetanus vaccine and blood samples were taken via jugular 
venipuncture immediately prior to vaccination (d 0) and on d 7, 14, 21 and 28 post-vaccination.  
Sera samples were measured for IgG(T), IgGa, IgGb, IgA, and IgM antibodies using an ELISA 
assay and data were analyzed using the PROC MIXED in SAS.  A P value of ≤ 0.05 was 
considered statistically significant.  Prior to vaccination, open mares tended to have higher 
IgG(T) specific antibody titers compared to pregnant mares (P = 0.07).  Previous research has 
shown that IgG antibody titers increase in response to vaccination with a variety of antigens.  
However, in this study, IgG(T) specific antibody titers decreased in response to vaccination, 
regardless of reproductive status or yeast supplementation. There was a difference due to diet (P 
= 0.002) but not when pregnancy was also included (P = 0.0775) There were no differences due 
to diet regardless of pregnancy with regard to IgA, IgM, IgGa, and  IgGb.  Overall, the dose of 1 
g/45.4 kg of BW per day of dietary yeast influence IgG(T) but not IgA, IgM, IgGa, and  IgGb 
specific antibody response in this study.  
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INTRODUCTION 
In the early 1970’s, many of the equine immunoglobulins were identified leading to the 
classification of IgGa, IgGb, IgG(T), IgA, and IgM (McGuire et al., 1973). Immunoglobulin (Ig) 
G is a major immunoglobulin found in equine serum (Sheoran et al, 1998). In general, IgG 
provides the longest protection of the immunoglobulins and is usually the first circulating 
antibody during a secondary immune response, or second exposure to a specific antigen (Nester, 
2004). Vaccination and immunization take advantage of the secondary response and can be used 
as a way to elicit an immune response (Nester, 2004). IgG protects the body through mechanisms 
such as complement activation, opsonization, aggregation, and pathogen immobilization. 
Recently, the subisotypes of equine IgG have been further divided into seven different isotypes 
due to the seven different genes that code for the constant heavy chain regions (Wagner et al, 
2004). Predominant IgG subisotypes in horse serum are IgGa, IgGb, and IgG(T) with IgGb being 
the most prominent followed by IgG(T) and lastly, IgGa (Sheoran et al 2000; Lewis et al., 2008).   
IgG(T) refers to the immunoglobulin  that comes from the exposure to tetanus toxoid 
immunization (Weir et al., 1966; Widders et al., 1986). IgGa and IgGb were differentially 
characterized by specific binding characteristics to staphylococci proteins A and G (Sheoran et 
al, 1996). IgGa is represented by one subclass, while both IgGb and IgG(T) are each represented 
by two of these subclasses (Wagner et al, 2006). However, since the classification of the 
different IgG subclasses, research involving mechanisms and specific functions of these 
subclasses is still largely unknown.  
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Immunoglobulin A (IgA) is associated with mucosal immunity and is known as the 
secretory immunoglobulin. In the horse, IgA can be found in the milk as well as other secretory 
areas such as the nasal passages (Lewis et al, 2010). Declines in serum IgA may be correlated 
with increased immunodeficiency symptoms (Flaminio et al., 2009). IgA levels have also been 
indicated as a means of evaluating the equine immunity (Tallmadge et al., 2009).  
Immunoglobulin M is a pentameric immunoglobulin and is often the first immunoglobulin 
produced in response to antigens. Due to the large structural size of IgM, this class of 
immunoglobulin acts primarily with infections in the blood stream and often elicits the classical 
pathway of the complement system (Nester, 2004). 
Equine immunoglobulins do not cross the placenta. Immunoglobulins are passively 
transferred to the foal through the mother’s milk, or colostrum. This passive transfer of immunity 
to young foals causes industry interest in increasing serum IgG concentrations in pregnant mares 
(McGuire et al., 1973; Bondo et al., 2011).  Foals need to ingest enough colostrum  containing 
immunoglobulins to prevent failure of passive transfer of antibodies to protect them from 
potential pathogenic invasion early in the life (McGuire et al., 1977; Crawford and Perryman, 
1980). Failure of passive transfer of immunoglobulins from mare to foal can be a significant and 
common immunodeficiency problem in horses that causes industry concern.  
In previous research studies, dietary yeast supplementation has been shown to act as an 
immunostimulant when fed daily in dairy cows. A slight increase in IgG subisotypes was seen 
with a slight decrease in non-specific IgA (Cakiroglu et al., 2010). Studies have shown that 
Saccharomyces cerevisae may elicit inflammatory immune responses and reduce mortality due 
to immune response in species other than horses such as pigs and feedlot steers (Emmanuel et al., 
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2007; Collier et al., 2011). Components of the yeast cell wall such as mannons and beta-glucans 
may be responsible for these immunostimulatory results (Kogan et al., 2007;Wismar et al., 
2010). However, little published research has been conducted with regard to horses.  
Horses are largely used for both recreational and breeding purposes. These two uses for 
horses, specifically mares, led to an interest in immunoglobulin levels for both pregnant and 
open (non-pregnant) mares. In the equine industry, dietary supplementation with commercially 
available products has become an increasingly popular way to attempt to improve animal health. 
The current study intended to examine the effects of commercially available yeast 
supplementation on the immune response associated with immune parameters such as 
immunoglobulins and more specifically IgG(T), IgGa, IgGb, IgA, and IgM in response to 
vaccination. 
 
 
MATERIALS AND METHODS 
 
Horses and Supplementation – Sixteen Quarter Horse mares (10.6 ± 5.0 yrs.) were used to 
evaluate the effect of dietary yeast supplementation on IgG(T), IgGa, IgGb, IgA, and IgM 
specific antibody responses.  Mares were blocked by reproductive status and diet and 
randomly assigned to one of two treatment groups: Yeast or Control.  Open mares will 
receive 0.5% BW of a 12% CP pelleted concentrate while pregnant mares will receive 
0.5% BW of a 16% CP pelleted concentrate.  All horses received mixed grass hay and 
water ad libitum.   Horses in the yeast treatment group were fed a target dose of 1 g/45.4 
kg of BW per day of a live culture of Saccharomyces cerevisiae throughout the study.  
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Vaccination and Serum Collection - After 60d (d 300 of gestation) of supplementation, mares 
were vaccinated with a commercial equine tetanus vaccine and blood samples were taken 
via jugular venipuncture immediately prior to vaccination (d 0) and on d 7, 14, 21 and 28 
post-vaccination. Blood samples were centrifuged at 10,000 rpm for 5 minutes and serum 
was decanted. Serum samples were then stored at  -80
o
C until further analysis.  
 
ELISA Kits –Serum samples were evaluated by the use of commercially available kits for 
equine serum: Horse IgG(T) ELISA Quantitation Set; Bethyl Laboratories Cat. No. E70-
105, Horse IgA ELISA Quantitation Set; Bethyl Laboratories Cat. No. E70-116, Horse 
IgM ELISA Quantitation Set; Bethyl Laboratories Cat. No. E70-114, Horse IgGa ELISA 
Quantitation Set; Bethyl Laboratories Cat. No. E70-124, Horse IgGb ELISA Quantitation 
Set; Bethyl Laboratories Cat. No. E70-127, and four parameter logistics curves. Serum 
samples were diluted in order to fit the curve set by the standards. Samples were run in 
duplicate for each ELISA.   All duplicate values were within 5% of each other.  
 
Data Analysis – Data were analyzed using the MIXED procedure of SAS v 9.3 (SAS 
Institute Inc., Cary, N.C.).  The model included the fixed effects of diets (1 df), 
pregnancy status (1 df), days of sampling (4 df) and all 2-way and 3-way interactions, 
plus a covariate measurement taken at the initiation of the trial (1 df), and the random 
effects of mare nested within diet and pregnancy(3 df) and the residual error (28 df).  The 
covariance structures were modeled using the CSH with IgG(T), CS with IgA, and AR(1) 
with IgGa, IgGb, and IgM  structure of errors.  The decision in regards to the best error 
structure was made based on the smallest Bayesian Information Criterion.  Comparisons 
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of the two diet treatments across all sampling days were made by decomposing the diet x 
days term into single degrees of freedom contrasts (i.e., using the SLICE option of the 
LSMEANS statement).  Other mean comparisons were made using Fisher’s protected 
least-significant difference (LSD).  Significance was declared at P < 0.05.  All results are 
expressed as least-squares means with the respective standard errors of the least means 
squares. 
 
RESULTS 
Serum IgG(T) Concentration 
Serum IgG(T) concentration between Yeast and Control mares at each time point 
are shown in Figures 1A and 1B. Open mares are presented in Figure 1A. Similar 
IgG(T) concentrations were seen d0 for both groups. Concentrations continued to be 
similar throughout the duration of the study; however, the trend for the two groups 
differed. The control diet group of mares exhibited a steady decline in serum IgG(T) 
concentration at all time points post-vaccination (P  < .0001). A slight increase at d28 
post-vaccination was seen for the open yeast supplemented mares.  
Pregnant mares are presented in Figure 1B. Pregnant mares that received the 
control diet appeared to start with a much lower IgG(T) concentration than the yeast 
supplemented group of mares. Concentrations between groups became more similar post 
d14. Again, the trends between the two groups differed. The pregnant mares that received 
the yeast diet exhibited a decrease until d21 and then a slight increase d28 post-
vaccination. The pregnant mares that received the control diet exhibited a trend that 
increased serum IgG(T) concentration until d14 and then a steady decrease was observed 
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through d28. Peak IgG(T) production appeared to be at d14 for the pregnant mares that 
received the control diet; however, peak production for the mares that received the yeast 
diet appeared to be day of vaccination. 
Among the different groups, the two yeast supplemented groups showed similar 
trends with slightly less variation between the pregnancy statuses of the animals. The 
control groups showed entirely different trends. Figure 6A shows IgG(T) concentrations 
for all four treatment groups at all time points. Overall, differences between diet were not 
significant when pregnancy status was taken into account (P = 0.0775). 
 
Serum IgGa Concentrations 
Serum IgGa concentration between Yeast and Control mares at each time point 
are shown in Figures 2A and 2B. The only difference was with regard to day post 
vaccination (P = 0.0148).There did not appear to be any differences due to dietary 
supplementation with regard to IgGa concentration (P = 0.481) Open mares are presented 
in Figure 2A.  There was no observable trend among the open mares that received the 
control diet. The open mares that received the diet containing yeast showed a slight trend. 
Serum IgGa concentration appeared to increase from d0 to d14, then decrease d14 to d28. 
Both Yeast and Control groups appeared to peak d14 post-vaccination. 
Pregnant mares are presented in Figure 2B. Pregnant mares that received the 
control diet showed an observable trend with an increase D0 to D14 and then a decrease 
d14 to d21 with a slight increase at d28. There was no observable pattern for the pregnant 
mares that received the yeast supplement. dO and d14 had similar IgGa concentrations. 
Both pregnant groups also peaked at d14. 
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Between the groups, trends were also similar. The open mares that received yeast 
exhibited a similar trend to the pregnant mares that received the control diet from d0 to 
d21. Similar trends were also seen d0 to d21 between the open control group and the 
pregnant yeast group. All groups saw a peak in serum IgGa concentration at d14. Figure 
6B shows IgGa concentrations for all four groups at all time points. 
 
Serum IgGb Concentrations 
 Serum IgGb concentration between Yeast and Control mares at each time point 
are shown in Figures 3A and 3B. No differences were seen between treatments (P = 
0.1326) or day post-vaccination (P = 0.1195) with regard to IgGb concentration. Open 
mares are presented in Figure 3A. Open mares that received the control diet showed a 
slight trend with an increase d0 to d14; however, the peak IgGb concentration was not 
seen until d28. The open mares that received the yeast supplement peaked at d14 then 
proceeded to decrease to d28. Both open groups had similar IgGb concentration on d7 
and d21. 
 Pregnant mares are presented in Figure 3B. Pregnant mares that received the 
control diet peaked at d14, then proceeded to decrease to decrease to d28. The pregnant 
mares that received yeast did not show an observable pattern. 
 Between the four different groups, more variation was seen across the pregnant 
groups than was seen across the open groups. Trends were similar between the open yeast 
and pregnant control groups d14 to d28; both of which peaked at D14. Figure 6C shows 
the IgGb concentration for all four groups at all time points. 
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Serum IgA Concentrations 
Serum IgA concentration between Yeast and Control mares at each time point are 
shown in Figures 4A and 4B. No differences were seen between treatments (P = 0.7901) 
or day post-vaccination (P = 0.6573) with regard to IgA concentration. Open mares are 
presented in Figure 4A. Open mares that received the control diet did not show an 
observable pattern; however, concentrations on d7 and d21were similar. The open mares 
that received the yeast supplement showed a relatively steady increase in IgA 
concentration from d0 through d28. Both open groups showed little variation d0, d14, and 
d28.  
Pregnant mares are presented in Figure 4B. Pregnant mares that received the 
control diet showed a relatively steady increase d0 through d28. Pregnant mares that 
received the yeast supplement had similar IgA concentrations on d14 and d21. 
Among the four groups, more variation was seen in pregnant rather than open 
groups. The trends in IgA concentration for open yeast mares and the pregnant control 
mares were similar. Figure 6D shows the IgA concentrations for all four groups. 
  
Serum IgM  Concentrations 
Serum IgM concentration between Yeast and Control mares at each time point are 
shown in Figures 5A and 5B. No differences were seen between treatments (P = 0.7752)  
or day post-vaccination (P = 0.1451) with regard to IgM concentration. Open mares are 
presented in Figure 5A. Open mares that received the control diet showed a peak of IgM 
at d7 with a decrease from d7 to d28. The open mares that received the yeast supplement 
showed a relatively steady increase d0 through d28.  
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Pregnant mares are presented in Figure 5B. Pregnant mares that received the 
control diet had peak IgM levels at d14, with a steady increase to that time point. The 
group that received yeast had a lesser increase through d14; however, both pregnant 
groups showed a peak at d14. Between all four groups, limited similarities were apparent. 
Figure 6E shows the IgM concentrations for all four groups. 
 
 
DISCUSSION 
  
Nutritional immunology or the use of nutritional products used to enhance the immune 
response has become an increasingly more popular means of enhancing previously used 
vaccines. Supplementation with a variety of products such as yeast and vitamin E has gained 
popularity among livestock owners. A variety of companies have been developing such 
supplemented products as well as potential doses. For the current study, a target dose of 1 g/ 
45.4 kg BW was consistent with the manufacturer’s instruction of a target dose of 10 g/ 454 
kg BW or close to 10 g/ day. Previous research in dairy cattle suggested that this dose was 
able to increase IgG serum concentration (Cakiroglu et al., 2010); however, in the current 
study, no differences between serum concentration and yeast supplementation were observed. 
Potentially, a higher dose of yeast may be necessary to elicit such an immune response. 
Overall, the levels of immunoglobulins seen in this study were consistent with previous 
studies with ranges between 200 mg/dL and 2000 mg/ dL for horses age 5-12 years 
(McFarlane et al., 2001; Mizukoshi et al, 2002; Tizzard, 2004; Petersson et al, 2010). IgGa, 
IgM, and IgG(T) tended to have slightly higher levels than previously seen with 
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immunostimulant supplementation (Petersson et al, 2010). This may have occurred because 
low serum levels of yeast may elicit an immune response through opsonization (Grondahl et 
al., 2001). IgGb tended to have lower serum levels than previously seen with the feeding of 
an immunostimulant (Petersson et al, 2010); however, this may have occurred because IgGb 
may be correlated with parasitemia control (Cunha et al., 2006).This may also partially 
explain why IgG(T) levels were high prior to vaccination. IgG(T) did not appear to increase 
throughout this study until near d28 post-vaccination. There appeared to be a steady decrease 
in IgG(T) concentration until d28 for the two yeast supplemented groups. Previous research 
has shown that IgG(T) may take over 4 weeks to peak post-infection or may not change in 
titer level over many months post-immunization (Cunha et al., 2006). The Pregnant control 
group did exhibit a peak in IgG(T) production near d14 post-vaccination. The remaining 
three treatment groups had the highest level d0 post-vaccination. The two yeast 
supplemented groups showed similar trends for IgG(T) with limited variation. Yeast 
supplementation may delay the peak production of IgG(T) post-vaccination until d28. 
Peak production of IgGa and IgGb seemed to occur near d14 for most of the treatment 
groups with the exception of open control group for IgGb. This is consistent with previous 
research involving immune responses to equine herpes virus as well as vaccination 
(Mizukoshi et al., 2002; Sheoran et al., 2003). Drawing comparisons between acute infection 
and vaccination is viable (Cunha et al., 2006). IgM peaked near d14  post-vaccination in both 
pregnant groups which is consistent with supplementation and vaccination response in older 
mares (Petersson et al., 2010). In the open control group, the peak was near d7, which is 
consistent with the well-known convention that IgM is the first antibody produced (Nester, 
2004). Potentially pregnancy and yeast supplementation may delay the production of IgM. 
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In the serum, overall levels of IgG(T), IgGa, and IgGb appeared similar. Previous 
research indicated that IgGb is the predominant subisotype of IgG in equine serum; however, 
in this study, a large difference in the subisotypes was not seen (Petersson et al, 2010; Lewis 
et al., 2008; Sheoran et al 2000). Other studies have shown that when challenged with 
immunological stimulants other than vaccination, IgG(T) may be the predominate subisotype 
as well as fluctuate in a manner that was seen in this study (Dowdall et al.,2002). 
Since IgA is the predominant immunoglobulin in nasal secretions rather than serum, 
different patterns in response to vaccination may have been seen if nasal swabs were 
analyzed along with serum (Sheoran et al., 2003). This may have given a more applicable 
analysis of IgA in response to yeast supplementation and vaccination; however, there were 
detectable levels of IgA in the serum and the concentration did appear to increase and 
slightly fluctuate.  
Overall, trends were similar for open yeast and pregnant control groups for IgGa, IgA, 
and IgGb. This may indicate that yeast supplementation in the open mares may mock the 
immunological effects of pregnancy. IgG(T) appeared to show different and almost opposite 
trends than what was seen for IgGa and IgGb. This may be partially due to the fact that 
IgG(T) levels are inversely related to IgG levels in equine serum (McGuire et al., 1971). This 
opposite or different trend may be due to the functionality of the separate subisotypes of 
equine IgG. IgG(T) may inhibit the action of IgGa and IgGb by competitively binding 
antigen  (McGuire et al., 1971; Lunn et al., 1998). IgM did not appear to show many trends 
across treatment groups. 
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CONCLUSION 
Overall, dietary yeast supplementation did not influence serum IgGa, IgGb, IgA, or IgM 
but did influence serum IgG(T) concentration in response to vaccination when fed at a target 
dose of 1 g/45.4 kg BW once daily. 
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Figure 1. 
Comparison of  serum IgG(T) concentration in mg/dL of open (A) and pregnant (B) mares 
between control and yeast supplemented diets from day of vaccination through D28  post 
vaccination (n= 4 per time point per group). Bars represent mean ± SE. Day Post Vaccination 
(PV)  P = <.0001; DIET*DayPV P = 0.002; PREG*DayPV P = 0.3328; DIET*PREG*DayPV       
P = 0.0775. 
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Figure 2. 
Comparison of  serum IgGa concentration in mg/dL of open (A) and pregnant (B) mares between 
control and yeast supplemented diets from day of vaccination through D28  post vaccination (n= 
4 per time point per group). Bars represent mean ± SE. Day Post Vaccination (PV) P = 0.0148; 
DIET*DayPV P = 0.2845; PREG*DayPV P = 0.7247; DIET*PREG*DayPV P = 0.4805. 
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Figure 3. 
Comparison of serum IgGb concentration in mg/dL of open (A) and pregnant (B) mares between 
control and yeast supplemented diets from day of vaccination through D28 post vaccination (n= 
4 per time point per group). Bars represent mean ± SE. Day Post Vaccination (PV) P = 0.1195; 
DIET*DayPV P = 0.2238; PREG*DayPV P = 0.708; DIET*PREG*DayPV  P = 0.1326. 
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Figure 4. 
Comparison of serum IgA concentration in mg/dL of open (A) and pregnant (B) mares between 
control and yeast supplemented diets from day of vaccination through D28 post vaccination (n= 
4 per time point per group). Bars represent mean ± SE.  Day Post Vaccination (PV) P = 0.6573; 
DIET*DayPV P = 0.6728; PREG*DayPV P = 0.8094; DIET*PREG*DayPV  P = 0.7901. 
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Figure 5. 
Comparison of serum IgM concentration in mg/dL of open (A) and pregnant (B) mares between 
control and yeast supplemented diets from day of vaccination through D28 post vaccination (n= 
4 per time point per group). Bars represent mean ± SE. Day Post Vaccination (PV) P = 0.1451; 
DIET*DayPV P = 0.5319; PREG*DayPV P = 0.3462; DIET*PREG*DayPV P = 0.7752. 
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Figure 6. 
Comparison of serum immunoglobulin concentration including IgG(T) (A), IgGa (B), IgGb (C), 
IgA (D) and IgM (E) of four treatment groups from day of vaccination through D28  post 
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vaccination (n= 4 per time point per group). Bars represent mean ± SE. P values shown in 
Figures 1-5. 
 
